Haptens

Small antigenic determinants capable of eliciting an immune response only when coupled to a carrier. Haptens bind to antibodies but by themselves cannot elicit an antibody response.

Also Known As:

Networked: 392 relevant articles (7 outcomes, 20 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Kaiserlian, Dominique: 10 articles (05/2012 - 03/2002)
2.	Nicolas, Jean-François: 9 articles (01/2012 - 03/2002)
3.	Vocanson, Marc: 8 articles (05/2012 - 05/2005)
4.	Cavani, Andrea: 8 articles (06/2010 - 01/2002)
5.	Low, Philip S: 7 articles (09/2009 - 05/2002)
6.	Lu, Yingjuan: 5 articles (09/2009 - 05/2002)
7.	Hennino, Anca: 5 articles (07/2009 - 02/2006)
8.	Girolomoni, Giampiero: 5 articles (11/2008 - 01/2002)
9.	Chavagnac, Cyril: 5 articles (06/2007 - 10/2003)
10.	Saint-Mezard, Pierre: 5 articles (04/2006 - 10/2003)

Related Diseases

1.	Neoplasms (Cancer) 05/01/2001 - "In this study we compared the effects of subinflammatory and inflammatory doses of solar-simulated ultraviolet (UV) radiation on enhancement of skin tumor growth, sensitization to haptens and cellular changes within the epidermis of C3H/HeN mice. " 05/01/2012 - "Visualization of tumors was achieved by the delivery of mono- and divalent radiolabeled haptens. " 02/15/2006 - "UV radiation of the skin impairs immune responses to haptens and to tumor Ags. " 11/15/1994 - "The three steps were: (a) anti-hapten mAb 2D12.5 (0 h); (b) polyvalent haptenprotein conjugate chase (20 h); and (c) 88Y-labeled monovalent DOTA or bivalent Janus-DOTA haptens (21 h) and organ and tumor bioassay (24 h). " 11/01/1992 - "Janus with 50 micrograms pretargeted Mab WC3A11 resulted in significantly higher murine tumor concentrations (approximately 7%/g) compared to monovalent haptens (approximately 1.4%/g, p < 0.001), and the same high tumor-to-background ratios (approximately 3/1). "
2.	Contact Dermatitis (Eczema, Contact) 01/01/2014 - "Contact hypersensitivity (CHS) induced by topical application of haptens is a commonly used model to study dermal inflammatory responses in mice. " 01/01/2012 - "Animal model of contact sensitivity (CS) is commonly used to study ACD in mice and can be induced by skin application of haptens. " 02/01/1995 - "These findings provide insight into the manner in which haptens are recognized by T cells involved in contact sensitivity and should facilitate the study and design of specific therapies for the manipulation of hapten-specific CD4+ T cell responses." 07/01/1994 - "Whether recognition of the haptens used to study allergic contact hypersensitivity in murine models similarly requires processing has not been determined. " 12/01/1984 - "In vivo studies with intact skin indicate that critical numbers of functioning Langerhans cells are essential for successful induction of contact hypersensitivity by epicutaneously applied haptens. "
3.	Anaphylaxis (Anaphylactic Shock) 05/01/1982 - "Guinea-pig anaphylaxis mediated by monovalent haptens with hydrocarbon auxiliary groups: studies on the difference in elicitation between intradermally and intravenously administered hapten." 01/01/1993 - "Preventing muscle relaxant anaphylaxis with monovalent haptens. " 04/01/1968 - "Anaphylactic reactions to univalent haptens." 02/29/1928 - "1. In passively sensitized animals bacterial anaphylaxis has been produced, in vivo and in vitro, with haptens from B. " 02/29/1928 - "ON THE ROLE OF CARBOHYDRATE HAPTENS IN BACTERIAL ANAPHYLAXIS."
4.	Hemolysis 01/01/1980 - "Improved methods are presented for the detection of antigens and haptens by the use of the passive hemolysis inhibition test. " 01/01/1981 - "Detection of antigens and haptens by inhibition of passive immune hemolysis." 01/01/1980 - "Immunoassay of antigens and haptens by inhibition of passive immune hemolysis." 02/01/2011 - "Nanoparticles may escape the phagocytic activity of macrophages, bind to serum proteins and act as haptens; activate complement cascades; disturb the Th1/Th2 balance; cause hemolysis or thrombogenecity and may perturb the adaptive or innate immunity leading to a hyper-activated immune state or even a suppressed immunophenotype. "
5.	Substance Withdrawal Syndrome (Withdrawal Symptoms) 06/01/2004 - "To prepare the holoantigens of morphine and morphine-6-succinyl, and to evaluate the efficacy of both of the haptens in eliciting immune responses and their effects on morphine withdrawal symptoms in male mice. "

Related Drugs and Biologics

1.	Antigens
2.	Immunoglobulin E (IgE)
3.	Dinitrochlorobenzene (DNCB)
4.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
5.	Interleukin-4 (Interleukin 4)
6.	Cyclosporine (Ciclosporin)
7.	HLA-DR Antigens (HLA-DR)
8.	Dexamethasone (Maxidex)
9.	Cholecalciferol (Vitamin D3)
10.	Morphine (MS Contin)

Related Therapies and Procedures

1.	Radioimmunotherapy
2.	Immunotherapy
3.	Intradermal Injections
4.	Immunomodulation
5.	Transplants (Transplant)